AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29245275 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus cisplatin plus radiotherapy (60-66 Gy/30 to 33 fractions)
Number of subjects: 88
Study 29245275 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus radiotherapy
Number of subjects: 88
Study 29245275 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus cisplatin plus radiotherapy
Number of subjects: 88
Study 25927378 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF‐LLIN (permethrin with pyriproxyfen)
Number of subjects: 0
Study 25927378 — intervention group
Group type: COMPARATOR
Intervention: LLIN (standard permethrin-treated long-lasting insecticidal net)
Number of subjects: 0
Study 25927378 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF‐LLIN
Number of subjects: 0
Study 23659225 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial messages with affective arguments
Number of subjects: 81
Study 23659225 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial messages with instrumental arguments
Number of subjects: 81
Study 23659225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhetorical messages with affective arguments
Number of subjects: 81
Study 23659225 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhetorical messages with instrumental arguments
Number of subjects: 81
Study 21228822 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemetric BP monitoring (TBPM)
Number of subjects: 60
Study 21228822 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 19641313 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilisation (VEM), commencing <24 hours
Number of subjects: 71
Study 19641313 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 71
Study 16447240 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose doxycycline (100 mg twice daily) plus methotrexate (MTX)
Number of subjects: 66
Study 16447240 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg twice daily) plus methotrexate (MTX)
Number of subjects: 66
Study 16447240 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 66
Study 15284947 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveofact(R) (n = 25)
Number of subjects: 50
Study 15284947 — intervention group
Group type: COMPARATOR
Intervention: Survanta(R) (n = 25)
Number of subjects: 50
Study 15284947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Alveofact(R) and Survanta(R)
Number of subjects: 50
Study 11461801 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of investigational drug
Number of subjects: 0
Study 11461801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of investigational drug
Number of subjects: 0
Study 11461801 — intervention group
Group type: COMPARATOR
Intervention: Investigational drug
Number of subjects: 0
Study 11461801 — intervention group
Group type: COMPARATOR
Intervention: Active control (e.g., carbamazepine or valproate)
Number of subjects: 0
Study 11461801 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drug (high dose)
Number of subjects: 0
Study 11461801 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational drug (low dose)
Number of subjects: 0
Study 9490558 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO)
Number of subjects: 0
Study 9490558 — intervention group
Group type: COMPARATOR
Intervention: oral iron therapy alone
Number of subjects: 0
Study 9490558 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO
Number of subjects: 0
Study 7930915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine mouthwash (5 mg three times a day)
Number of subjects: 20
Study 7930915 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (Saliva Orthana)
Number of subjects: 20
Study 3555627 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue, 15 mg/day
Number of subjects: 0
Study 3555627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31200814 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 628
Study 28760787 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support interventions including patient decision aids for primary endocrine therapy vs surgery/antioestrogen therapy and chemotherapy vs no chemotherapy, and a clinical treatment outcomes algorithm for clinicians.
Number of subjects: 0
Study 24038574 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured group reading programme
Number of subjects: 41
Study 23663881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immunoglobulin (HBIG; three 200 IU intramuscular injections given at four-week intervals starting from gestation week 28)
Number of subjects: 1355
Study 23663881 — intervention group
Group type: COMPARATOR
Intervention: No HBIG injection
Number of subjects: 1355
Study 23663881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1355
Study 23663881 — intervention group
Group type: COMPARATOR
Intervention: Artificial formula feeding
Number of subjects: 1355
Study 23663881 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg-positive mothers
Number of subjects: 1355
Study 23663881 — intervention group
Group type: COMPARATOR
Intervention: HBeAg-negative mothers
Number of subjects: 1355
Study 23663881 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA-positive mothers
Number of subjects: 1355
Study 23663881 — intervention group
Group type: COMPARATOR
Intervention: HBV DNA-negative mothers
Number of subjects: 1355
Study 23663881 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum HBV DNA ≥ 10⁷ copies/mL
Number of subjects: 1355
Study 23663881 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum HBV DNA 10³-10⁶ IU/ml
Number of subjects: 1355
Study 23663881 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum HBV DNA < 10³ IU/ml
Number of subjects: 1355
Study 21205884 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion cues for detecting inflation/deflation of rigid and flexing cylinders
Number of subjects: 0
Study 21205884 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational model based on motion perspective
Number of subjects: 0
Study 21205884 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric velocity profiles
Number of subjects: 0
Study 21205884 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice with motion cues
Number of subjects: 0
Study 19701510 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Protect Bond
Number of subjects: 14
Study 19701510 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond
Number of subjects: 14
Study 17374672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.4 +/- 1.1 mL/d)
Number of subjects: 64
Study 17374672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 64
Study 17374672 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk
Number of subjects: 64
Study 15515337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling device at lateral force of 0.5 N
Number of subjects: 102
Study 15515337 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling device at lateral force of 2.0 N
Number of subjects: 102
Study 15515337 — intervention group
Group type: EXPERIMENTAL
Intervention: Curets at lateral force of 0.5 N
Number of subjects: 102
Study 15515337 — intervention group
Group type: EXPERIMENTAL
Intervention: Curets at lateral force of 2.0 N
Number of subjects: 102
Study 15515337 — intervention group
Group type: COMPARATOR
Intervention: Untreated samples (control)
Number of subjects: 102
Study 11136912 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine levels in patients with focal cerebral ischemia
Number of subjects: 16
Study 11136912 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study 9141919 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0
Study 9141919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0
Study 9141919 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 9141919 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 9141919 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study 8179165 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 67
Study 8179165 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 67
Study 8179165 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/Fentanyl
Number of subjects: 67
Study 2896423 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil (50 micrograms)
Number of subjects: 0
Study 2896423 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil
Number of subjects: 0
Study 2896423 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 0
Study 31841875 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Youth with NF (RY-NF)
Number of subjects: 51
Study 31841875 — intervention group
Group type: COMPARATOR
Intervention: Health Education for NF (HE-NF)
Number of subjects: 51
Study 29723105 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic administration for 4 weeks
Number of subjects: 45
Study 29723105 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration for 4 weeks
Number of subjects: 45
Study 29723105 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 45
Study 26583954 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10 sessions
Number of subjects: 181
Study 25520127 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐day standard triple therapy plus bismuth and probiotic
Number of subjects: 100
Study 25520127 — intervention group
Group type: COMPARATOR
Intervention: 7‐day standard triple therapy with placebo
Number of subjects: 100
Study 25520127 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐day standard triple therapy plus bismuth and probiotic
Number of subjects: 100
Study 22906281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic postconditioning (4 episodes of inflation and deflation of the angioplasty balloon)
Number of subjects: 62
Study 22906281 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional intervention)
Number of subjects: 62
Study 20533525 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 128
Study 18698245 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG interferon alpha 2b (1.0 microg/kg per week), ribavirin (800 mg/d) plus amantadine (200 mg/d)
Number of subjects: 50
Study 18698245 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG interferon alpha 2b (1.0 microg/kg per week) plus ribavirin (800 mg/d)
Number of subjects: 50
Study 18698245 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both groups)
Number of subjects: 50
Study 18698245 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who achieved SVR
Number of subjects: 50
Study 18698245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 50
Study 15854180 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b combined with lamivudine 100 mg/day
Number of subjects: 300
Study 15854180 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon alpha-2b combined with placebo
Number of subjects: 300
Study 15854180 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2b
Number of subjects: 300
Study 12440763 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring with 24-hour Holter ECG on the second postoperative day-evening-night
Number of subjects: 44
Study 10472473 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-power laser (50 mW, 830 nm, 10 min per session)
Number of subjects: 49
Study 10472473 — intervention group
Group type: COMPARATOR
Intervention: Placebo low-power laser
Number of subjects: 49
Study 8740313 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 900 U kg‐1 week‐1 with 6 mg kg‐1 day‐1 of iron for 4 weeks
Number of subjects: 29
Study 8740313 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 29
Study 1554117 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 150
Study 1554117 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 mg)
Number of subjects: 150
Study 3893343 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866
Study 3893343 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study 31350701 — intervention group
Group type: EXPERIMENTAL
Intervention: IoCRRT
Number of subjects: 60
Study 31350701 — intervention group
Group type: COMPARATOR
Intervention: SOC
Number of subjects: 60
Study 31350701 — intervention group
Group type: EXPERIMENTAL
Intervention: IoCRRT (per-protocol analysis)
Number of subjects: 60
Study 31350701 — intervention group
Group type: COMPARATOR
Intervention: SOC (per-protocol analysis)
Number of subjects: 60
Study 29342163 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxylamine-pyridoxine (10 mg doxylamine and 10 mg pyridoxine, taken 2-4 times per day for 14 days)
Number of subjects: 140
Study 29342163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablet taken with the same instructions)
Number of subjects: 140
Study 24222508 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-factor version of the Partner Interaction Questionnaire (PIQ)
Number of subjects: 0
Study 24222508 — intervention group
Group type: COMPARATOR
Intervention: Two-factor version of the Partner Interaction Questionnaire (PIQ)
Number of subjects: 0
Study 22271159 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dapagliflozin
Number of subjects: 54
Study 22271159 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg)
Number of subjects: 54
Study 22271159 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (320 mg)
Number of subjects: 54
Study 22271159 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg)
Number of subjects: 54
Study 22271159 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.25 mg)
Number of subjects: 54
Study 19913785 — intervention group
Group type: EXPERIMENTAL
Intervention: ENBD group
Number of subjects: 104
Study 19913785 — intervention group
Group type: COMPARATOR
Intervention: no-ENBD group
Number of subjects: 104
Study 17565585 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying chromocolonoscopy
Number of subjects: 500
Study 17565585 — intervention group
Group type: COMPARATOR
Intervention: Conventional chromocolonoscopy
Number of subjects: 500
Study 15657158 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment (6 to 9 million U, 3 times weekly for 26 to 88 weeks)
Number of subjects: 345
Study 15657158 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 345
Study 12038949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education
Number of subjects: 106
Study 12038949 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive education
Number of subjects: 106
Study 12038949 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (no education)
Number of subjects: 106
Study 9706913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 2 g
Number of subjects: 150
Study 9706913 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 7 million KIU
Number of subjects: 150
Study 9706913 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 150
Study 8031109 — intervention group
Group type: EXPERIMENTAL
Intervention: C.A.R.E. program
Number of subjects: 195
Study 2623215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine administered intravenously or topically using iontophoresis or occlusive dressing
Number of subjects: 17
Study 31376834 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated marking (SensoMotoric Instruments - SMI)
Number of subjects: 132
Study 31376834 — intervention group
Group type: COMPARATOR
Intervention: Manual marking
Number of subjects: 132
Study 28452885 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic-targeted hypothermia treatment (MTHT) group, targeting 50% to 60% rest metabolic ratio
Number of subjects: 88
Study 28452885 — intervention group
Group type: COMPARATOR
Intervention: Body temperature-targeted hypothermia treatment (BTHT) group, targeting body temperature of 32°C to 35°C
Number of subjects: 88
Study 26151440 — intervention group
Group type: EXPERIMENTAL
Intervention: SibworkS program (n=30)
Number of subjects: 56
Study 26151440 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n=26)
Number of subjects: 56
Study 23250821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 23250821 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study 23250821 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination exercise
Number of subjects: 0
Study 21584438 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise combined with whole-body vibration at 30 Hz (R+V30)
Number of subjects: 9
Study 21584438 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (R)
Number of subjects: 9
Study 18438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential monotherapy (group 1)
Number of subjects: 508
Study 18438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-up combination therapy (group 2)
Number of subjects: 508
Study 18438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate, sulfasalazine, and prednisone (group 3)
Number of subjects: 508
Study 18438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate and infliximab (group 4)
Number of subjects: 508
Study 16284067 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 mg rectally, given as three doses every 12 hours starting the night prior to embryo transfer
Number of subjects: 136
Study 16284067 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard specifications without indomethacin)
Number of subjects: 136
Study 12676418 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional treatment protocol delivered by nurse practitioners (NP)
Number of subjects: 203
Study 12676418 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care from primary care physician
Number of subjects: 203
Study 10902984 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed milk + micronutrients (E)
Number of subjects: 136
Study 10902984 — intervention group
Group type: EXPERIMENTAL
Intervention: Skimmed milk + micronutrients (M)
Number of subjects: 136
Study 10902984 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk (S)
Number of subjects: 136
Study 8931393 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural environment simulation
Number of subjects: 0
Study 8931393 — intervention group
Group type: COMPARATOR
Intervention: Urban environment simulation
Number of subjects: 0
Study 8451248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-relieving products (specific types not mentioned)
Number of subjects: 0
Study 8451248 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials of commonly used beds and overlays
Number of subjects: 0
Study 3948474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE), 0.5 mg im, twice a day from the day of surgery until full mobilization achieved
Number of subjects: 162
Study 3948474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 3948474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 162
Study 29889718 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive perfusion enhancement system
Number of subjects: 431
Study 29889718 — intervention group
Group type: COMPARATOR
Intervention: Alternating pressure beds (control)
Number of subjects: 431
Study 26391030 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal tobacco treatment education (MME)
Number of subjects: 1096
Study 26391030 — intervention group
Group type: COMPARATOR
Intervention: Traditional tobacco treatment education (TE)
Number of subjects: 1096
Study 24741578 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL/IL-2
Number of subjects: 88
Study 24741578 — intervention group
Group type: COMPARATOR
Intervention: IL-2
Number of subjects: 88
Study 22368136 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (peer mentoring on Trinity hypotensive ultrasound protocol between months 0 and 2)
Number of subjects: 86
Study 22368136 — intervention group
Group type: COMPARATOR
Intervention: Late intervention group (peer mentoring on Trinity hypotensive ultrasound protocol between months 2 and 4)
Number of subjects: 86
Study 20210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous running
Number of subjects: 6
Study 20210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Football
Number of subjects: 6
Study 20210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval running
Number of subjects: 6
Study 20210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 6
Study 20210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sports
Number of subjects: 6
Study 20210905 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual sports
Number of subjects: 6
Study 18762327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 474
Study 18762327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp lactis HN019
Number of subjects: 474
Study 18762327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 474
Study 15556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 60
Study 15556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 15556965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 12127922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 350
Study 12127922 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 350